Gilead Sciences sets aside $200 million for a potential settlement over its HIV drug promotional speaker program amid federal ...

Onctura, a clinical-stage biopharmaceutical company combating neglected and hard-to-treat cancers, today announces the appointments of Elizabeth Holt as Chief Business Officer (CBO) and Dr Mark ...

Past the halfway point the 2025 Colorado legislative session, the days are getting longer and the debates are growing more ...

The Government of Canada continues to make significant investments in Canada's biomanufacturing and life sciences sector to develop innovative solutions and long-term domestic biomanufacturing ...

Under the new leadership of chairman ... Roche entered into a collaboration agreement with Gilead Sciences, who had discovered oseltamivir, the primary antiviral drug used to combat avian ...

Gilead Sciences recently experienced a significant ... showcasing Gilead’s leadership in complex disease areas. In addition to these product and partnership milestones, Gilead's ongoing share ...

Medical pioneer Gilead Sciences has seen its stock etch out ... especially considering Gilead's EPS growth, industry leadership, and reasonable P/E valuation. Why Haven't You Looked at Zacks ...

Investors with a lot of money to spend have taken a bullish stance on Gilead Sciences GILD. And retail traders should know. We noticed this today when the trades showed up on publicly available ...